Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic target for managing metabolic syndromes. These naturally occurring molecules are secreted by the gut in response to meal intake, stimulating insulin release and suppressing glucagon release. GLP-1 peptides possess promising therapeutic outcomes in treating type 2 diabe